Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 20
Filter
1.
Mucosal Immunol ; 8(1): 18-28, 2015 Jan.
Article in English | MEDLINE | ID: mdl-25354320

ABSTRACT

Over the past 25 years, studies led in humans have considerably improved our understanding of celiac disease, a complex disease that is generally defined as an autoimmune-like enteropathy induced by dietary gluten in genetically predisposed individuals. Recently, large efforts were also invested in the development of mouse models in order to explore pathogenic hypotheses, and also with the goal to design pretherapeutic models that could be used to test innovative therapies. Yet, modeling this complex multifactorial disease has been a very challenging task. Herein, we review how approaches in rodents have provided insight into celiac disease pathophysiology and also highlight the difficulties met to fully recapitulate the human disease.


Subject(s)
Celiac Disease/immunology , Disease Models, Animal , Animals , Diet , Gene-Environment Interaction , Genetic Predisposition to Disease , Glutens/immunology , Humans , Mice , Rats
2.
Aliment Pharmacol Ther ; 40(9): 1103-9, 2014 Nov.
Article in English | MEDLINE | ID: mdl-25199794

ABSTRACT

BACKGROUND: Recently, a new enteropathy has been described: olmesartan-associated enteropathy. However, the association has been questioned: a phase 3 trial and a cohort study found no association between gastrointestinal events and olmesartan. AIM: To collect French cases of sartan-associated enteropathy to describe further this entity, confirm or refute causality, and determine if the association exists with other sartans. METHODS: French gastroenterologists were invited to report cases of sartan-associated enteropathy and collect clinical, biological and histological data. Patients with diarrhoea and histological duodenal abnormalities were included. RESULTS: Thirty-six patients with olmesartan-associated enteropathy were reported, including 32 with villous atrophy and four without. There was only one patient with irbesartan-associated enteropathy. None of the patients died. Patients with villous atrophy had diarrhoea, vomiting, renal failure, hypokalaemia, body weight loss and hypoalbuminaemia. Thirty-one patients were hospitalised; four required intensive care. Anti-transglutaminase and anti-enterocyte antibodies were negative; anti-nuclear antibodies were positive (9/11). Endoscopic duodenal biopsies showed villous atrophy (32/32) and polyclonal intra-epithelial CD3+CD8+ lymphocytosis (11/11). Exactly, 14/15 patients responded to steroids and/or immunosuppressants, prescribed because of suspected autoimmune enteropathy. Ten olmesartan interruptions were followed by reintroductions before steroids or immunosuppressants. Interruptions were followed by remissions (9/10), but reintroductions were followed by relapses (9/9). Twenty-nine patients were in remission since olmesartan interruption, including 26 without immunosuppressants. Patients with normal villi had similar clinical characteristics, but mild histological abnormalities (intra-epithelial lymphocytosis and lamina propria lymphocytic infiltration). CONCLUSIONS: Olmesartan causes a severe and immune-mediated enteropathy, with or without villous atrophy. Enteropathy associated with other sartans seems to be very rare.


Subject(s)
Angiotensin II Type 1 Receptor Blockers/adverse effects , Data Collection , Gastrointestinal Diseases/chemically induced , Gastrointestinal Diseases/epidemiology , Imidazoles/adverse effects , Tetrazoles/adverse effects , Adult , Aged , Aged, 80 and over , Cohort Studies , Data Collection/methods , Diarrhea/chemically induced , Diarrhea/diagnosis , Diarrhea/epidemiology , Female , France/epidemiology , Gastrointestinal Diseases/diagnosis , Humans , Intestinal Mucosa/drug effects , Intestinal Mucosa/pathology , Male , Middle Aged
3.
Mucosal Immunol ; 7(2): 315-24, 2014 Mar.
Article in English | MEDLINE | ID: mdl-23839063

ABSTRACT

In celiac disease, enhanced permeability to gliadin peptides can result from their apico-basal transport by secretory immunoglobulin A1 (SIgA1) binding to the CD71 receptor ectopically expressed at the gut epithelial surface. Herein, we have established a mouse model in which there is apico-basal transport of the model antigen ovalbumin (OVA) by specific SIgA1 and have analyzed local T-cell activation. Transgenic DO11.10 mice were grafted with a hybridoma-secreting OVA-specific humanized IgA1, which could bind mouse CD71 and which were released in the intestinal lumen as SIgA. CD71 expression was induced at the gut apical surface by treating the mice with tyrphostin A8. Following gavage of the mice with OVA, OVA-specific CD4⁺ T cells isolated from the mesenteric lymph nodes displayed higher expression of the activation marker CD69 and produced more interferon gamma in mice bearing the hybridoma-secreting OVA-specific IgA1, than in ungrafted mice or in mice grafted with an irrelevant hybridoma. These results indicate that the protective role of SIgA1 might be jeopardized in human pathological conditions associated with ectopic expression of CD71 at the gut surface.


Subject(s)
Immunoglobulin A, Secretory/immunology , Immunoglobulin A, Secretory/metabolism , Intestinal Mucosa/immunology , Intestinal Mucosa/metabolism , Ovalbumin/metabolism , Th1 Cells/immunology , Animals , Antigens, CD/metabolism , CD4-Positive T-Lymphocytes/immunology , Celiac Disease/immunology , Celiac Disease/metabolism , Disease Models, Animal , Enterocytes/drug effects , Enterocytes/metabolism , Female , Humans , Lymph Nodes/immunology , Mesentery , Mice , Mice, Transgenic , Protein Binding , Protein Transport , Receptors, Transferrin/metabolism , Tyrphostins/pharmacology , Up-Regulation/drug effects
4.
Gastroenterol Clin Biol ; 34(11): 590-605, 2010 Nov.
Article in English | MEDLINE | ID: mdl-21050687

ABSTRACT

INTRODUCTION: Enteropathy-associated T-cell lymphoma (EATL) is a rare complication of celiac disease (<1% of lymphomas) and has a poor prognosis. METHODS: International literature review with PubMed search (up to January 2009) of pathophysiological, clinical and therapeutic data. RESULTS: EATL is found in patients with a mean age of 59 years, often with a complication that signals its diagnosis. Refractory celiac disease (RCD), equivalent to low-grade intraepithelial T-cell lymphoma, could be an intermediary between celiac disease and high-grade invasive T-cell lymphoma. The median survival is 7 months, with no significant difference between stages; the cumulative 5-year survival is less than 20%. The poor prognosis is determined by disease that has often spread before it is diagnosed (50%), multifocal involvement of the small bowel (50%), poor general health status and undernutrition, and recurrence of complications (infections, perforations, gastrointestinal haemorrhages, occlusions), thus delaying the chemotherapy and contributing to frequent chemotherapy resistance. There is currently no effective and consensual treatment: preventive surgery for complications is controversial, and the results of chemotherapy are disappointing. The classic CHOP protocol (combination of doxorubicin-cyclophosphamide-vincristine-prednisone) does not have satisfactory results and survival remains poor, especially in patients with underlying RCD. High-dose chemotherapy with autotransplantion seems to only improve the prognosis in localised forms. Allogeneic bone marrow transplantation was not evaluated. In all, 1/3 of patients, being unfit for treatment, die before 3 months and half of treated patients stop chemotherapy prematurely due to inefficacy, intolerance and/or complications. CONCLUSION: Improvement of the prognosis requires collaboration in order to compose a national cohort, to evaluate new diagnostic and therapeutic strategies and to define prognostic factors.


Subject(s)
Celiac Disease , Lymphoma, T-Cell , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Celiac Disease/complications , Celiac Disease/diagnosis , Celiac Disease/physiopathology , Celiac Disease/therapy , Humans , Lymphoma, T-Cell/complications , Lymphoma, T-Cell/diagnosis , Lymphoma, T-Cell/physiopathology , Lymphoma, T-Cell/therapy , Prognosis , Risk Assessment , Risk Factors , Transplantation, Autologous/methods
5.
Gastroenterol Clin Biol ; 33(8-9): 635-47, 2009.
Article in French | MEDLINE | ID: mdl-19682814

ABSTRACT

Celiac disease is an enteropathy related to autoimmune diseases induced by gluten in genetically predisposed individuals. Its prevalence is of 1% in Europe and United States. Its clinical presentation is extremely various and diagnosis relies on the detection of specific serum antibodies and on the demonstration of intestinal villous atrophy. Treatment relies on a life-long gluten free diet which prevents bone, autoimmune and malignant complications. The keystone of its pathogenesis is the interaction of gliadin peptides with HLA DQ2/8 molecules, the main genetic risk factor, which induces the activation of CD4+ T-cells in the lamina propria. Yet, complementary mechanisms are necessary to provoke the loss of tolerance to gluten which involves the cytokine IL-15 responsible of the activation/expansion of intraepithelial lymphocytes, a hallmark of the origin of the severe lymphomatous complications. The burden of the gluten-free diet leads to a strong demand for alternative treatments. Numerous strategies have been identified to prevent the recognition of gliadin peptides by the immune system. Their efficiency and safety remained to be evaluated, the most attainable strategy today being oral therapy by enzymes able to eliminate gluten immunogenicity.


Subject(s)
Celiac Disease , Celiac Disease/diagnosis , Celiac Disease/etiology , Celiac Disease/history , Celiac Disease/physiopathology , Celiac Disease/therapy , Forecasting , History, 19th Century , History, 20th Century , History, 21st Century , Humans
6.
Mucosal Immunol ; 2(1): 8-23, 2009 Jan.
Article in English | MEDLINE | ID: mdl-19079330

ABSTRACT

Celiac disease is a multifactorial disorder and provides a privileged model to decipher how the interplay between environmental and genetic factors can alter mucosal tolerance to a food antigen, lead to chronic intestinal inflammation, and ultimately promote T-cell lymphomagenesis. Here we summarize how HLA-DQ2/8 molecules, the main genetic risk factor for this disease can orchestrate a CD4(+) T-cell adaptive immune response against gluten, and discuss recent data which shed light on the innate and adaptive immune stimuli that collaborate to induce a proinflammatory TH1 response, a massive expansion of intraepithelial lymphocytes, and a cytolytic attack of the epithelium. The intestinal immune response driven in genetically predisposed patients by chronic exposure to gluten emerges as the pathological counterpart of normal acute intestinal responses to intracellular pathogens.


Subject(s)
Autoimmunity/immunology , Celiac Disease/complications , Celiac Disease/immunology , Immune Tolerance/immunology , Inflammatory Bowel Diseases/immunology , Lymphoma/immunology , Mouth Mucosa/immunology , Animals , Humans , Inflammatory Bowel Diseases/complications , Lymphoma/complications
7.
Parasite ; 15(3): 389-95, 2008 Sep.
Article in English | MEDLINE | ID: mdl-18814712

ABSTRACT

Toxoplasma gondii is an intracellular parasite that frequently infects a large spectrum of warm-blooded animals. This parasite induces abortion and establishes both chronic and silent infections, particularly in the brain. Parasite penetration into the host activates a strong anti-parasite immune response. In the present paper, we will discuss the interplay between innate and adaptive immunity that occurs within the infected intestine to clear the parasite and to maintain intestinal homeostasis despite the exacerbation of an inflammatory immune response.


Subject(s)
Immunity, Mucosal , Toxoplasma/immunology , Toxoplasma/physiology , Toxoplasmosis/immunology , Animals , Cytokines/immunology , Homeostasis/immunology , Humans , Intestinal Mucosa/immunology , Intestinal Mucosa/parasitology
8.
Curr Top Microbiol Immunol ; 298: 139-56, 2006.
Article in English | MEDLINE | ID: mdl-16323414

ABSTRACT

NKG2 receptors and their ligands play an essential role in the control of CTL activation in the tissue microenvironment. We discuss the regulation of NKG2 receptor expression by CTL and how uncontrolled activation of NKG2 receptors can lead to organ-specific autoimmune and inflammatory disorders.


Subject(s)
Receptors, Immunologic/metabolism , T-Lymphocytes, Cytotoxic/immunology , Autoimmunity , Humans , In Vitro Techniques , Interleukin-15/metabolism , Killer Cells, Natural/immunology , Ligands , Models, Immunological , NK Cell Lectin-Like Receptor Subfamily C , NK Cell Lectin-Like Receptor Subfamily D/metabolism , Receptors, Antigen, T-Cell/metabolism , Receptors, Natural Killer Cell , Signal Transduction/immunology , Tissue Distribution
9.
Gut ; 50(1): 25-8, 2002 Jan.
Article in English | MEDLINE | ID: mdl-11772962

ABSTRACT

BACKGROUND: Endoscopic recurrence after surgery in Crohn's disease is frequent and unpredictable. Abnormal intestinal production of pro- (interleukin (IL)-1 beta, tumour necrosis factor alpha (TNF-alpha)) and anti- (IL-10) inflammatory cytokines has been associated with severe outcome in experimental models of colitis. PATIENTS AND METHODS: We evaluated if ileal TNF-alpha, IL-1 beta, or IL-10 mRNA levels measured at the time of surgery predict endoscopic recurrence, and if ileal IL-10 levels are associated with particular IL-10 promoter alleles. Ileal biopsies were obtained peroperatively from the healthy neoileum of patients undergoing a right ileocolectomy for Crohn's disease. Mucosal TNF-alpha, IL-1 beta, and IL-10 mRNA levels were quantified by competitive polymerase chain reaction. A cut off value was determined using a receiver operating curve. IL-10.G promoter haplotypes were analysed using a polymorphic dinucleotide repeat in the IL-10 promoter region. RESULTS: Three months after surgery, 53% of patients had endoscopic recurrence while 47% remained free of disease. The risk of endoscopic recurrence correlated with ileal IL-10 mRNA concentrations (r(2)=0.81). Endoscopic recurrence occurred more frequently in patients classified as low IL-10 producers than in those that were high producers (80% v 40%) (p=0.02). Patients with at least one of the two alleles G7-8 or G10-13 produced, respectively, higher (p=0.006) and lower (p=0.029) ileal IL-10 mRNA. The distribution of IL-10.G microsatellite genotypes was similar in patients with or without endoscopic recurrence. CONCLUSION: Low ileal IL-10 mRNA concentration is a good marker of endoscopic recurrence in Crohn's disease but the distribution of IL-10.G haplotypes cannot predict the postoperative evolution of the disease.


Subject(s)
Crohn Disease/metabolism , Interleukin-10/analysis , Interleukin-1/analysis , Tumor Necrosis Factor-alpha/analysis , Adult , Alleles , Analysis of Variance , Female , Haplotypes , Humans , Intestinal Mucosa/metabolism , Male , Microsatellite Repeats , Predictive Value of Tests , Promoter Regions, Genetic , RNA, Messenger/analysis , ROC Curve , Recurrence , Reverse Transcriptase Polymerase Chain Reaction , Statistics, Nonparametric
10.
Hum Immunol ; 62(7): 694-700, 2001 Jul.
Article in English | MEDLINE | ID: mdl-11423175

ABSTRACT

Crohn disease is a chronic inflammatory bowel disease that involves all the intestine but predominantly alters the ileum. The disease largely depends on T cells, but the biologic role of intestinal intraepithelial lymphocytes (IEL) in transmural inflammation remains poorly characterized. To address this issue, a comparison of IEL and lamina propria lymphocytes (LPL) isolated from the uninvolved and the inflamed ileal mucosa of Crohn disease patients was performed. More CD8+ IEL (26% versus 8%) from the inflamed ileal mucosa expressed the CD28 receptor and the CD11a integrin than IEL from the uninvolved ileal mucosa, which were mostly CD28-. IEL had longer telomeres in the inflamed than in the uninvolved areas and a TCR Vbeta repertoire more similar to circulating T cells, suggesting that the increased proportion of CD28+ TCRalphabeta+ IEL within the inflamed mucosa is more likely due to recruited lymphocytes from the periphery that populate the epithelial layer than to the acquisition of the CD28 molecule by activated resident lymphocytes. In the uninvolved ileal mucosa, IEL from Crohn disease patients had shorter telomeric lengths than IEL from control patients, suggesting that they have been chronically stimulated. Such perturbation of the IEL population within the ileal mucosa could contribute to the inflammation in Crohn disease.


Subject(s)
CD28 Antigens/biosynthesis , Cell Movement/immunology , Crohn Disease/immunology , Ileum/pathology , Intestinal Mucosa/immunology , Intestinal Mucosa/pathology , Lymphocyte Subsets/immunology , Telomere , Adult , Aged , Aged, 80 and over , Cell Movement/genetics , Crohn Disease/genetics , Crohn Disease/pathology , Female , Humans , Ileum/cytology , Ileum/immunology , Ileum/metabolism , Inflammation/genetics , Inflammation/immunology , Inflammation/pathology , Intestinal Mucosa/cytology , Intestinal Mucosa/metabolism , Lymphocyte Subsets/cytology , Lymphocyte Subsets/metabolism , Lymphocyte Subsets/pathology , Male , Middle Aged , Receptors, Antigen, T-Cell, alpha-beta/biosynthesis , Telomere/metabolism , Telomere/pathology
13.
Acta Chir Belg ; 74(4): 406-21, 1975 Jul.
Article in French | MEDLINE | ID: mdl-1146461

ABSTRACT

This work groups 126 cases of malignant melanomas operated since 1967. Seventy-seven cases responding to 2 criterions were selected: reexamination of the primary pathologic sample of melanoma according to 4 tests of histoprognosis and adequate follow-up of the patient. Histoprognostic criterions according to Clark and Mihm were the histogenetic type, the level of invasion plus vascular embolic neoplastic invasion and the notion of mitotic index. Four main conclusions emerged: Statistical notion of a critical period situated between the 12th and 30th month, during which 40% of patients die, especially those with primary tumor of histogenetic type NM (nodular melanoma) or SSM (superficial spreading melanoma) and invasion stage IV and V. Assurance of the value of histoprognosis in the primary cognition of tumoral determinism. A new precision in the decision of systematic node excision in invasion stages IV and V, and in stages III with high mitotic index. Reasonable and early use of all therapeutic means in cases with unfavourable histoprognosis.


Subject(s)
Melanoma/pathology , Skin Neoplasms/pathology , Follow-Up Studies , Humans , Lymphatic Metastasis , Melanoma/mortality , Melanoma/therapy , Prognosis , Skin Neoplasms/mortality , Skin Neoplasms/therapy , Time Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...